Cargando…

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brauneck, Franziska, Weimer, Pauline, Schulze zur Wiesch, Julian, Weisel, Katja, Leypoldt, Lisa, Vohwinkel, Gabi, Fritzsche, Britta, Bokemeyer, Carsten, Wellbrock, Jasmin, Fiedler, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606547/ https://www.ncbi.nlm.nih.gov/pubmed/34820398 http://dx.doi.org/10.3389/fmed.2021.763773

Ejemplares similares

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML
por: Brauneck, F., et al.
Publicado: (2021)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
por: Brauneck, Franziska, et al.
Publicado: (2023)

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
por: Latuske, Emily-Marie, et al.
Publicado: (2017)

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
por: Stamm, Hauke, et al.
Publicado: (2018)

OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021)

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
por: Wellbrock, Jasmin, et al.
Publicado: (2021)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia
por: Freisleben, Fabian, et al.
Publicado: (2021)

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
por: Ghandili, Susanne, et al.
Publicado: (2021)

Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
por: Wellbrock, Jasmin, et al.
Publicado: (2014)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients
por: Jin, Zhenyi, et al.
Publicado: (2020)

Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
por: Zhang, Yiwei, et al.
Publicado: (2019)

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis
por: Modemann, Franziska, et al.
Publicado: (2022)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia
por: Freisleben, Fabian, et al.
Publicado: (2020)

HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules
por: Ackermann, Christin, et al.
Publicado: (2019)

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
por: Xu, Liangjing, et al.
Publicado: (2017)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
por: Yu, Lihua, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition
por: Wildner, Nils H., et al.
Publicado: (2022)

The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
por: Gonçalves Silva, Isabel, et al.
Publicado: (2017)

Decreased Frequency of Intestinal CD39(+) γδ(+) T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease
por: Libera, Jana, et al.
Publicado: (2020)

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
por: Dama, Paola, et al.
Publicado: (2019)

B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19
por: Wildner, Nils H, et al.
Publicado: (2020)

Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease
por: Herrmann, Marissa, et al.
Publicado: (2020)

Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma
por: Xie, Xiaolin, et al.
Publicado: (2023)

Acute Myeloid Leukemia and the Bone Marrow Niche—Take a Closer Look
por: Behrmann, Lena, et al.
Publicado: (2018)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
por: Rakova, Jana, et al.
Publicado: (2021)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n4mg9jdt92ec3usm9cv43tgaft